ZNTL
Zentalis Pharmaceuticals, Inc.Healthcare·Biotechnology
$4.00
$285M market cap
Revenue
$0.0M
Free Cash Flow
$-63.9M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination wit
2-Year Price History
$4.06-61.8%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -37.9 | -37.9 | -35.4 | -33.0 | -33.0 | -0.0 | 211.8 | 34.7 | 70.3 | -215.4% | -- | -- |
| Act | 2025-Q4 | 0.0 | -37.2 | -37.4 | -35.2 | -30.9 | -30.9 | -0.0 | 245.9 | 39.6 | 71.7 | -136.2% | -- | -- |
Valuation & Metrics
Market Stats
Price$4.00
Market Cap$285M
Enterprise Value$108M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-22.5%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-70.6M
Free Cash Flow$-63.9M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-175.8%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares5.5M
Days to Cover3.9
Change (vs Prior)+5.4%
Need at least 2 settlement dates for chart
Employees
Headcount166
Revenue / Employee$0
Gross Profit / Employee$-910
Cash Runway
39.8months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
29.7%(+4.0% YoY)
87 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
4.5%(-1.6% YoY)
9 filers
Vanguard, iShares, SPDR
Market makers
0.9%(+0.6% YoY)
5 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| 5AM Venture Management, LLC | $9.2M | $4.68 | +$0 | +$8.1M | +1.1% | $360M |
| Squadron Capital Management LLC | $8.5M | $2.34 | +$8.5M | +$8.5M | +16.9% | $250M |
| TWO SIGMA INVESTMENTS, LP | $6.9M | $3.47 | +$3.5M | +$5.6M | -0.9% | $117.03B |
| ACADIAN ASSET MANAGEMENT LLC | $6.7M | $2.17 | −$2K | +$407K | -0.5% | $70.48B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $5.4M | $2.34 | +$5.4M | +$5.4M | — | $4.04T |
| RENAISSANCE TECHNOLOGIES LLC | $4.5M | $3.89 | −$2.2M | +$2.6M | +1.2% | $63.91B |
| CITADEL ADVISORS LLC | $4.1M | $11.43 | −$543K | +$3.9M | -0.4% | $138.22B |
| D. E. Shaw & Co., Inc. | $3.5M | $3.53 | −$412K | +$857K | -0.3% | $118.02B |
| Opaleye Management Inc. | $3.3M | $3.56 | +$27K | −$1.3M | +1.0% | $759M |
| Decheng Capital LLC | $3.1M | $11.56 | +$0 | −$1.6M | -0.3% | $661M |
| MILLENNIUM MANAGEMENT LLC | $3.0M | $4.92 | +$1.4M | −$4.2M | -0.5% | $127.40B |
| BlackRock, Inc.Passive | $3.0M | $3.67 | +$46K | −$6.9M | -0.2% | $5.69T |
| Ishara Investments LP | $2.9M | $1.35 | −$211K | +$2.9M | +2.1% | $99.0M |
| BANK OF AMERICA CORP /DE/ | $2.6M | $5.59 | −$550K | +$5K | -0.1% | $1.36T |
| PRIMECAP MANAGEMENT CO/CA/ | $2.2M | $7.14 | +$0 | −$719K | +0.4% | $127.01B |
| PFIZER INC | $2.0M | $3.03 | +$0 | +$0 | +4.4% | $239M |
| Connor, Clark & Lunn Investment Management Ltd. | $1.9M | $2.56 | +$12K | +$1.0M | +0.6% | $43.38B |
| Qube Research & Technologies Ltd | $1.5M | $5.22 | +$1.4M | +$1.5M | +0.3% | $70.36B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $1.5M | $19.46 | +$75K | −$1.7M | +2.3% | $1.61T |
| GSA CAPITAL PARTNERS LLP | $1.5M | $2.35 | −$1.3M | +$184K | -5.9% | $1.61B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
+2.10%
avg per quarter
Holders (ex-self)
+2.04%
excl. this stock
Buyers (this Q)
+6.42%
50 buyers · $0.04B in
Sellers (this Q)
+0.44%
32 sellers · $-0.01B out
alpha coverage: 93% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-3.3%
how holders react when this stock falls
On quiet Qs
+10.1%
−10% to +10% baseline
On rallies (+10%+)
-5.2%
how they react when this stock rises
Holders' portfolio flow this Q
+7.2%
inflows — adds are organic
Sellers' portfolio flow this Q
+8.2%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-9.3%
Holder mid (any stock)
-6.0%
Holder rally (any stock)
-8.6%
Biggest decreases this quarter
RENAISSANCE TECHNOLOGIES LLC−$2.2Mα+1.2GSA CAPITAL PARTNERS LLP−$1.3Mα-5.9BANK OF AMERICA CORP /DE/−$550Kα-0.1CITADEL ADVISORS LLC−$543Kα-0.4D. E. Shaw & Co., Inc.−$412Kα-0.3Ishara Investments LP−$211Kα+2.1OPAL CAPITAL LLCexited−$173KJACOBS LEVY EQUITY MANAGEMENT, INCexited−$168KWalleye Capital LLCexited−$149KALGERT GLOBAL LLCexited−$65K
New buyers this quarter
Top-5 holders · 36.1%
5AM Venture Management, LLC--
Squadron Capital Management LLC--
TWO SIGMA INVESTMENTS, LP--
ACADIAN ASSET MANAGEMENT LLC--
VANGUARD CAPITAL MANAGEMENT LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
FMR LLC284KMatrix Capital Management Company, LP—PRICE T ROWE ASSOCIATES INC /MD/—Avidity Partners Management LP—TYBOURNE CAPITAL MANAGEMENT (HK) LTD—EVENTIDE ASSET MANAGEMENT, LLC—VIKING GLOBAL INVESTORS LP—PRIMECAP MANAGEMENT CO/CA/957KCapital International Investors—FEDERATED HERMES, INC.66K
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (1 analysts)$10.0015000.0%
Last Year (2 analysts)$6.005000.0%
Current Price$4.00
Analyst Ratings
8
4
Buy: 8Hold: 4Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$135K
9 txns · 3 insiders · 55,372 sh
Major holders (≥10% beneficial owners)
Buys ($, 12mo)
$7.75M
1 txn · 1 insider · 6,459,973 sh
Sells ($, 12mo)
$9.97M
1 txn · 1 insider · 7,500,000 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-02-10 | SELL | Vultaggio Vincent | officer: PAO and PFO | 6,894 | $2.42 | $17K | $355K |
| 2026-02-09 | SELL | Bruns Ingmar | officer: Chief Medical Officer | 335 | $2.39 | $802 | $80K |
| 2026-02-09 | SELL | EASTLAND JULIA MARIE | director, officer: CEO & President | 889 | $2.39 | $2K | $189K |
| 2026-02-09 | SELL | Vultaggio Vincent | officer: PAO and PFO | 3,379 | $2.39 | $8K | $367K |
| 2026-02-06 | SELL | Bruns Ingmar | officer: Chief Medical Officer | 2,962 | $2.43 | $7K | $82K |
| 2026-02-06 | SELL | EASTLAND JULIA MARIE | director, officer: CEO & President | 7,866 | $2.43 | $19K | $194K |
| 2026-02-06 | SELL | Vultaggio Vincent | officer: PAO and PFO | 29,951 | $2.43 | $73K | $381K |
| 2026-02-03 | SELL | Vultaggio Vincent | officer: PAO and PFO | 556 | $2.52 | $1K | $470K |
| 2026-02-02 | SELL | Vultaggio Vincent | officer: PAO and PFO | 2,540 | $2.55 | $6K | $478K |
| 2025-12-31 | BUY | WALTERS GROUP | 10 percent owner | 6,459,973 | $1.20 | $7.75M | $16.21M |
| 2025-12-15 | SELL | Matrix Capital Management Company, LP | 10 percent owner | 7,500,000 | $1.33 | $9.97M | $8.59M |
Order Flow (FINRA, ~3w lag)
26.4%retail-0.4pp
20.9%dark+2.4pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Zentalis Pharmaceuticals: Bone-Cutting and Asset Liquidation in a High-Stakes Burn Race
Overall Risk
7/10
Fraud
2/10
Dilution
8/10
Insolvency
5/10
Earnings Overstated
3/10
Hidden Liabilities
4/10
Legal
3/10
Audit Warnings
6/10
Hidden Upside
4/10
Contextually Acceptable
4/10